Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)
主要な著者: | Dutton, S, Blazeby, J, Petty, R, Mansoor, W, Thompson, J, Harrison, M, Abbas, H, Dahle-Smith, A, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Harvey, C, Julier, P, Jankowski, J, Midgley, R, Ferry, DR, Grp, C |
---|---|
フォーマット: | Journal article |
出版事項: |
2013
|
類似資料
-
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
著者:: Dutton, S, 等
出版事項: (2014) -
Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer
著者:: Petty, R, 等
出版事項: (2017) -
Gefitinib and EGFR gene copy number aberrations in esophageal cancer
著者:: Petty, RD, 等
出版事項: (2017) -
Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
著者:: Mei-Chuan Tang, 等
出版事項: (2015-01-01) -
Busting the Breast Cancer with AstraZeneca’s Gefitinib
著者:: S. Chemmalar, 等
出版事項: (2023-01-01)